February 7, 2019

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Kind Attn.: Mr. Avishkar Naik/ Ms. Deepa Kandoi

Dear Sir/Madam,

Re: Clarification /Confirmation on news item appearing in "Media/Publication".

We refer to your emails dated February 7, 2019, seeking clarifications as regards the news item which appeared on **www.moneycontrol.com** today, captioned **'Lupin falls 4% as US FDA issues observations to Pithampur unit'**.

We wish to state that, the Company, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, had already intimated your Exchange, on January 26, 2019, that the US FDA inspection, carried out between January 14 and January 25, 2019, at Pithampur Unit - 2 (Indore) facility, closed with 6 observations.

Copy of the captioned Press Release dated January 26, 2019, is enclosed for your ready reference.

Trust we have clarified the matter.

Thanking you,

Yours faithfully,
For LUPIN LIMITED

ACS11973)

R. V. SATAM
COMPANY SECRETARY

LUPIN LIMITED MUMBAI INDIA

Encl.: a/a

Press Release

LUPIN

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPCIN

U.S. FDA completes inspection of Lupin's Pithampur Unit-2 (Indore) facility

Mumbai, January 26, 2019: Pharma major Lupin announced today the completion of the United States Food and Drug Administration (U.S. FDA) inspection carried out at its Pithampur Unit -2 (Indore) facility. The inspection was carried out between January 14 and January 25, 2019.

The inspection at Pithampur Unit-2 (Indore) closed with 6 observations. The Company is confident of addressing the observations satisfactorily.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 13th largest generics pharmaceutical company in terms of market capitalization (30th September 2018, Bloomberg) and the 8th largest generics pharmaceutical company in terms of revenues (30th June 2018, Bloomberg LTM) globally. The Company is the 3rd largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT September 2018); 3rd largest Indian pharmaceutical company by global revenues (30th June 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan (IQVIA MAT September 2018) and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2018).

For the financial year ended 31st March, 2018, Lupin's Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

Arvind Bothra
Head – Investor Relations
Email:
arvindbothra@lupin.com
Ph: +91-22-66402137

*Safe Harbor Statement